Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling

This exploratory analysis of the phase 3 TALAPRO-2 trial (n=805) assessed ctDNA and circulating tumor cells in metastatic castration-resistant prostate cancer. Detectable ctDNA tumor fraction at baseline was associated with shorter radiographic progression-free survival (HR 2.46 with talazoparib plus enzalutamide; HR 4.03 with placebo plus enzalutamide). Week 9 conversion from ctDNA-positive to negative was prognostic for improved radiographic progression-free survival in both arms, and homologous recombination repair alteration status agreed in 84% (421 of 501) of patients evaluable by both tissue and ctDNA tests. This is a metastatic tumor-fraction analysis, not postoperative MRD.

The Lancet OncologyPubMed 42950862DOI 10.1016/S1470-2045(26)00355-4